Asenapine transdermal - Hisamitsu Pharmaceuticals

Drug Profile

Asenapine transdermal - Hisamitsu Pharmaceuticals

Alternative Names: HP-3070

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Class Antipsychotics; Heterocyclic compounds with 4 or more rings; Oxepins; Pyrrolidines; Small molecules
  • Mechanism of Action Dopamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Schizophrenia

Most Recent Events

  • 18 Nov 2016 Noven Pharmaceuticals completes a phase-I clinical trial in Schizophrenia in USA and United Kingdom (Transdermal) (JapicCTI-142525)
  • 01 Aug 2016 Phase-III clinical trials in Schizophrenia in USA (Transdermal) (NCT02876900)
  • 24 Apr 2014 Phase-I clinical trials in Schizophrenia in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top